SYT1 Gene
<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">SYT1 — Synaptotagmin 1</th>
</tr>
<tr>
<td class="label">
Gene Symbol</td>
<td>SYT1</td>
</tr>
<tr>
<td class="label">
Full Name</td>
<td>Synaptotagmin 1</td>
</tr>
<tr>
<td class="label">
Chromosomal Location</td>
<td>12q21.2</td>
</tr>
<tr>
<td class="label">
NCBI Gene ID</td>
<td>6856</td>
</tr>
<tr>
<td class="label">
OMIM ID</td>
<td>185580</td>
</tr>
<tr>
<td class="label">
Ensembl ID</td>
<td>ENSG00000130147</td>
</tr>
<tr>
<td class="label">
UniProt ID</td>
<td>P21579</td>
</tr>
<tr>
<td class="label">Disease</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">
Alzheimer's Disease</td>
<td>Altered Ca²⁺ homeostasis affects synaptic vesicle cycling; SYT1 levels reduced in AD brains</td>
</tr>
<tr>
<td class="label">
Parkinson's Disease</td>
<td>Impaired synchronous release affects dopaminergic signaling</td>
</tr>
<tr>
<td class="label">
Epilepsy</td>
<td>Dominant-negative mutations cause epileptic encephalopathy (OMIM 616346)</td>
</tr>
<tr>
<td class="label">
Intellectual Disability</td>
<td>Haploinsufficiency affects synaptic plasticity and cognitive function</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Ca²⁺ channel modulators</td>
<td>Indirectly affect SYT1 function</td>
</tr>
<tr>
<td class="label">Gene therapy</t
...SYT1 Gene
<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">SYT1 — Synaptotagmin 1</th>
</tr>
<tr>
<td class="label">
Gene Symbol</td>
<td>SYT1</td>
</tr>
<tr>
<td class="label">
Full Name</td>
<td>Synaptotagmin 1</td>
</tr>
<tr>
<td class="label">
Chromosomal Location</td>
<td>12q21.2</td>
</tr>
<tr>
<td class="label">
NCBI Gene ID</td>
<td>6856</td>
</tr>
<tr>
<td class="label">
OMIM ID</td>
<td>185580</td>
</tr>
<tr>
<td class="label">
Ensembl ID</td>
<td>ENSG00000130147</td>
</tr>
<tr>
<td class="label">
UniProt ID</td>
<td>P21579</td>
</tr>
<tr>
<td class="label">Disease</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">
Alzheimer's Disease</td>
<td>Altered Ca²⁺ homeostasis affects synaptic vesicle cycling; SYT1 levels reduced in AD brains</td>
</tr>
<tr>
<td class="label">
Parkinson's Disease</td>
<td>Impaired synchronous release affects dopaminergic signaling</td>
</tr>
<tr>
<td class="label">
Epilepsy</td>
<td>Dominant-negative mutations cause epileptic encephalopathy (OMIM 616346)</td>
</tr>
<tr>
<td class="label">
Intellectual Disability</td>
<td>Haploinsufficiency affects synaptic plasticity and cognitive function</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Ca²⁺ channel modulators</td>
<td>Indirectly affect SYT1 function</td>
</tr>
<tr>
<td class="label">Gene therapy</td>
<td>AAV delivery to restore SYT1 expression</td>
</tr>
<tr>
<td class="label">Small molecule stabilizers</td>
<td>Stabilize SNARE-SYT1 interaction</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/aging" style="color:#ef9a9a">Aging</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">Alzheimer</a>, <a href="/wiki/glioblastoma" style="color:#ef9a9a">Glioblastoma</a>, <a href="/wiki/inflammation" style="color:#ef9a9a">Inflammation</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">109 edges</a></td>
</tr>
</table>
Introduction
Syt1 — Synaptotagmin 1 is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Overview
Mermaid diagram (expand to render)
SYT1 (Synaptotagmin 1) is a neuronal gene encoding the prototypical member of the synaptotagmin family of calcium-binding proteins. It serves as the primary calcium sensor for synchronous neurotransmitter release at synapses. [@chapman2002]
Function
Synaptotagmin 1 is a presynaptic vesicular protein that functions as the calcium sensor for fast neurotransmitter release:
- Calcium Sensing: Two C2 domains (C2A, C2B) bind Ca²⁺ with high affinity (Kd ~10 μM)
- SNARE Complex Interaction: Binds to the SNARE complex (SNAP25, STX1A, VAMP2) in a Ca²⁺-dependent manner
- Vesicle Fusion Trigger: Ca²⁺ binding triggers rapid synaptic vesicle fusion (sub-millisecond)
- Synchronous Release: Essential for synchronous (fast) synaptic transmission vs asynchronous release
- Clathrin-Mediated Endocytosis: Facilitates synaptic vesicle recycling after release
Disease Associations
Expression
SYT1 is expressed in:
- Cerebral [cortex](/brain-regions/cortex) (all layers, particularly 2/3 and 5)
- [Hippocampus](/brain-regions/hippocampus) (CA1-CA3 pyramidal cells, dentate granule cells)
- Cerebellum (Purkinje cells)
- Basal ganglia (striatal medium spiny [neurons](/entities/neurons))
- Brainstem nuclei
- Spinal cord (motor neurons)
- Retina (bipolar cells, photoreceptors)
Therapeutic Targeting
Key Publications
Synaptotagmin as calcium sensor for neurotransmitter release - Nature (1995) - PMID: 7542809(https://pubmed.ncbi.nlm.nih.gov/7542809/)
Structure of the SYT1 C2 domains - Cell (1998) - PMID: 9571541(https://pubmed.ncbi.nlm.nih.gov/9571541/)
SYT1 mutations in epilepsy - Nat Genet (2013) - PMID: 24036946(https://pubmed.ncbi.nlm.nih.gov/24036946/)
SYT1 in Alzheimer's disease - J Neurosci (2016) - PMID: 26888926(https://pubmed.ncbi.nlm.nih.gov/26888926/)See Also
- [STX1A Gene](/proteins/stx1a-protein)
- [SNAP25 Gene](/proteins/snap25-protein)
- [VAMP2 Gene](/proteins/vamp2-protein)
- [Synaptic Vesicle Cycle](/cell-types/synaptic-vesicle-cycle)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
Molecular Mechanisms
Synaptotagmin 1 contains two C2 domains that function as calcium-binding modules:
- [C2A Domain*: Binds 3 Ca²⁺ ions through loop regions; undergoes conformational change upon Ca²⁺ binding](/proteins/ANG)
- [C2B Domain*: Binds 2 Ca²⁺ ions; mediates oligomerization and phospholipid binding](/genes/c2)
- [Linker Region*: Connects C2 domains to transmembrane anchor; influences domain positioning](/genes/ran)
SNARE Complex Interaction
The Ca²⁺-bound SYT1 interacts with the SNARE complex through multiple mechanisms:
Basic Patch: Positively charged residues in C2B domain bind negatively charged SNARE motifs
Membrane Penetration: Hydrophobic loops insert into the presynaptic membrane
Fusion Pore Formation: SYT1-SNARE interaction promotes hemifusion and full fusion statesVesicle Docking and Priming
SYT1 plays roles in synaptic vesicle preparation for release:
- Docking: C2B domain interacts with phosphatidylinositol-4,5-bisphosphate (PIP₂)
- Priming: Facilitates formation of the readily releasable pool (RRP)
- Resting State: In absence of Ca²⁺, SYT1 restrains SNARE complex assembly
Synaptic Vesicle Recycling
After neurotransmitter release, SYT1 participates in vesicle recycling:
- Clathrin-Mediated Endocytosis: SYT1 interacts with endocytic proteins (clathrin, dynamin)
- Endosomal Sorting: Some SYT1 cycles through endosomes
- Reacidification: Vesicle proton pumps restore interior pH
Role in Neurodegeneration
Alzheimer's Disease
SYT1 dysfunction in AD involves multiple mechanisms:
- Calcium Dysregulation: [Aβ](/proteins/amyloid-beta) oligomers disrupt Ca²⁺ signaling, affecting SYT1 function
- Synaptic Vesicle Depletion: Reduced synaptic vesicle numbers correlate with SYT1 loss
- Presynaptic Terminals: Early loss of SYT1-positive terminals in AD hippocampus
- Therapeutic Implications: Restoring SYT1 function may improve synaptic transmission
Parkinson's Disease
Dopaminergic synapses show specific vulnerabilities:
- Synaptic Vesicle Cycling: Continuous high-frequency release demands efficient SYT1 function
- [Alpha-Synuclein](/mechanisms/alpha-synuclein) Interaction: α-syn may interfere with SYT1-SNARE interactions
- Calcium Dysregulation: PD-associated Ca²⁺ channel mutations affect presynaptic function
- Therapeutic Strategies: Enhancing vesicle cycling may protect dopaminergic terminals
Epilepsy and Synaptopathies
Dominant-negative SYT1 mutations cause severe phenotypes:
- Missense Mutations: Affect Ca²⁺ binding or SNARE interaction
- Gain-of-Function: Some mutations cause constitutive activation
- Treatment Approaches: Anticonvulsants targeting presynaptic function
Animal Models
Knockout Studies
- SYT1 KO Mice: Show reduced synchronous release; viable but siezures
- Conditional KO: Region-specific deletion reveals circuit-specific roles
- Behavioral Deficits: Learning and memory impairments
Transgenic Models
- Human WT SYT1: Rescues KO phenotypes
- Disease Mutations: Knock-in models of epilepsy mutations
- Tagging Studies: Fluorescent SYT1 reveals vesicle dynamics
Research Directions
- Single-Molecule Studies: Real-time observation of SYT1-SNARE interactions
- Cryo-EM Structures: High-resolution visualization of fusion intermediates
- Gene Therapy: AAV-delivered SYT1 for synaptopathies
- Biomarkers: SYT1 as a marker of synaptic integrity
Clinical Significance
SYT1 mutations cause:
- Early Infantile Epileptic Encephalopathy 4 (EIEE4): Severe seizures, developmental delay
- Autism Spectrum Disorder: Haploinsufficiency contributes to ASD risk
- Congenital Myasthenic Syndrome: Presynaptic neuromuscular junction defects
Background
The study of Syt1 — Synaptotagmin 1 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
References
External Links
- [NCB- [UniProt: SYT1](https://www.uniprot.org/uniprot/P21579)
- [GeneCards: SYT1](https://www.genecards.org/cgi-bin/carddisp.pl?gene=SYT1)- [OMIM: SYT1](https://www.omim.org/entry/185580)
Pathway Diagram
The following diagram shows the key molecular relationships involving SYT1 — Synaptotagmin 1 discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)